Stocks · News reference
Vistagen Says Exploratory Phase 2 Repeat Dose Study Of Fasedienol Missed Statistical Significance On Primary Endpoint (p=0.2); Reports Nominal Significance In Very Severe Social Anxiety Subgroup
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Vistagen Therapeutics, Inc. (VTGN)
Filed: 2026-10-30 AccNo: 0001628280-26-068627 Size: 140 KB Item 2.05: Cost Associated with Exit or Disposal Activities Item 8.01: Other Events
Vistagen shares are trading lower. The company announced it presented exploratory data at Psych Congress 2026 highlighting potential efficacy signal for fasedienol nasal spray in patients with severe social anxiety disorder.
Vistagen Presents Exploratory Data At Psych Congress 2026 Highlighting Potential Efficacy Signal For Phase 3 Fasedienol Nasal Spray In Patients With Very Severe Social Anxiety Disorder
Exploratory research results presented at Psych Congress 2026 in New OrleansFull poster presentation can be found on "Publications" section of Company’s websiteSOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE
Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data
Vistagen reports positive preliminary Phase 3 data showing fasedienol nasal spray reduces social anxiety with strong safety results.
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.